CHAPEL HILL – All hands are on deck for innovative treatments and tests for SARS-CoV2 and the COVID-19 it causes, and researchers from the University of North Carolina are no exception. A team from UNC is involved in the development of an antiviral drug that shows promise of reducing severe lung damage caused by the respiratory virus. The study is now expected to move to human trials in the spring.
The drug is called EIDD-2801 for now. The senior author of the drug study is a Ralph Baric the William R. Kenan Jr. Distinguished Professor of epidemiology at UNC Chapel Hill.
“This new drug not only has high potential for treating COVID-19 patients, but also appears effective for the treatment of other serious coronavirus infections.” Epidemiologist Ralph Baric
With any luck, this is one of several viable and effective treatments for COVID-19 to be developed in the coming weeks and months. A vaccine is not expected to be available for the novel virus for another year or more.
You can read the full study (bring a medical dictionary) from the researchers here.